Ranibizuman 0.5 mg

DRUG2 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Branch Retinal Vein OcclusionCentral Retinal Vein Occlusion

Phase 2

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

CompletedNCT04667897

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Branch Retinal Vein Occlusion

Start: 2021-01-28End: 2022-07-13Updated: 2025-06-27

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

CompletedNCT04667910

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Central Retinal Vein Occlusion

Start: 2021-01-27End: 2022-11-16Updated: 2025-06-27

Related Papers

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.

2025-12-25